Comparison of Dilapan-S and laminaria for cervical priming before surgical pregnancy termination at 17-22 weeks' gestation

Dennis G Chambers, Robin J Willcourt, Anthony R Laver, Jane K Baird, Wye Y Herbert, Dennis G Chambers, Robin J Willcourt, Anthony R Laver, Jane K Baird, Wye Y Herbert

Abstract

Methods: A retrospective analysis of medical records of three consecutive cohorts of women. All cohorts received a digoxin feticide injection on Day 1. Two cohorts were treated with laminaria, cohort A of 151 women over 1-2 days and cohort B of 52 women over 1-3 days, and cohort C of 151 women was treated with Dilapan-S over 1-3 days.

Results: Adequate cervical priming for dilatation and evacuation (D&E) on Day 2 was achieved in 98% of the Dilapan-S cohort and 56% of cohort A and 40% of the cohort B laminaria cohorts. Return to theater for D&E 3-4 hours after dilator insertion on Day 2 occurred in 62.3% of Dilapan-S cohort C and 9.3% of cohort A and 4% of cohort B laminaria cohorts (P = 0.001). A mean D&E theater time of 19 minutes for laminaria cohort A was reduced by 10.1% in the Dilapan-S cohort C (P = 0.02). The incidence of unscheduled overnight delivery outside the clinic was 0% for Dilapan-S and 1.3% for cohort A and 3.8% for cohort B laminaria cohorts (P = 0.14).

Conclusion: Dilapan-S osmotic dilators are superior to laminaria in producing more cervical priming and dilatation in a shorter time. This enables 17-22 week D&E procedures to be carried out in fewer days and in shorter theater times. They also eliminate the risk of an unscheduled overnight delivery outside the clinic.

Keywords: Dilapan-S; cervical priming; dilatation and evacuation; laminaria tents; late second-trimester surgical abortion; osmotic dilators.

Figures

Figure 1
Figure 1
Dilapan-S before and after hydration.
Figure 2
Figure 2
Laminaria tents before and after hydration.

References

    1. Gamble SB, Strauss LT, Parker WY, et al. Centers for Disease Control and Prevention (CDC) Abortion surveillance: United States, 2005. MMWR Surveill Summ. 2008;57:1–32.
    1. Lohr PA. Surgical abortion in the second trimester. Reprod Health Matters. 2008;16:151–161.
    1. Pridmore BR, Chambers DG. Uterine perforation during surgical abortion: review of diagnosis, management and prevention. Aust N Z J Obstet Gynaecol. 1999;39:349–353.
    1. Hern WM. Laminaria, induced fetal demise and misoprostol in late abortion. Int J Gyneol Obstet. 2001;75:279–286.
    1. Molaei M, Jones HE, Weiselberg T, et al. Effectiveness and safety of digoxin to induce fetal demise prior to second-trimester abortion. Contraception. 2008;77:223–225.
    1. Newmann SJ, Dalve-Endres A, Diedrich JT, et al. Cervical preparation for second trimester dilatation and evacuation. Cochrane Database Syst Rev. 2010;8:CD007310.
    1. Chasen ST, Kalish RB, Gupta M, et al. Dilatation and evacuation at ≥20 weeks: comparison of operative techniques. Am J Obstet Gynecol. 2004;190:1180–1183.
    1. Hayes JL, Fox MC. Cervical dilatation in second-trimester abortion. Clin Obstet Gynecol. 2009;52:171–178.
    1. Wilson LC, Meyn LA, Creinin MD. Cervical preparation for surgical abortion between 12 and 18 weeks gestation using vaginal misoprostol and Dilapan-S. Contraception. 2011;83:511–516.
    1. Carbonell JL, Gallego FG, Llorente MP, et al. Vaginal vs sublingual misoprostol with mifepristone for cervical priming in second-trimester abortion by dilatation and evacuation: a randomized clinical trial. Contraception. 2007;75:230–237.
    1. Lohr PA, Hayes JL, Gemzell-Danielsson K. Surgical versus medical methods for second trimester induced abortion. Cochrane Database Syst Rev. 2008;23(1):CD006714.
    1. Bryant AG, Grimes DA, Garrett JM, Stuart GS. Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilatation and evacuation. Obstet Gynecol. 2011;117:788–792.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren